C3 Jian, Inc., a biotechnology company focused on reengineering the human microbiome to deliver novel health-care products, announced it has preliminary data in a current phase 2 clinical trial for its novel drug, C16G2. C16G2 targets the specific elimination of Streptococcus mutans, the acid-producing bacterium associated with dental caries or tooth decay.

(Visited 17 times, 1 visits today)